Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms by Histologic Type 1Neoplasms 1Multiple Myeloma 1Lymphoma, Mantle-Cell 1Lymphoma 1Hematologic Neoplasms 1Hematologic Diseases 1Fallopian Tube Neoplasms 1Blood Protein Disorders 1

Interventions

Paclitaxel 20Carboplatin 16liposomal doxorubicin 10Bevacizumab 10Gemcitabine 8Topotecan 7Taxes 7Cisplatin 7pembrolizumab 6Doxorubicin 5Cyclophosphamide 5Nivolumab 4fludarabine 3Oxaliplatin 3Immunoglobulin G 3Hyperthermic Intraperitoneal Chemotherapy 3Disulfides 3Cytoreduction Surgical Procedures 3trebananib 2talazoparib 2rucaparib 2peginterferon alfa-2b 2olaparib 2fludarabine phosphate 2aldesleukin 2Surgical Procedures, Operative 2STA 9090 2Platinum 2Lenalidomide 2Irinotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Fallopian Tube Neoplasms × ricolinostat × Clear all
NCT02661815 2019-11-08

A Phase 1b Study of Paclitaxel And Ricolinostat For The Treatment Of Gynecological Cancer

Dana-Farber Cancer Institute

Phase 1 Terminated
6 enrolled 8 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡